Introduction {#Sec1}
============

Heat shock proteins occur in all known life forms, and their main role is to facilitate the folding of other proteins both under normal and stressful conditions. Consequently, some heat shock proteins are induced by cellular stress, thus protecting cells against adverse effects. The role of heat shock proteins in the survival of intracellular parasites extends beyond maintenance of proteostasis, as they are also implicated in the development and pathogenesis of these organisms (reviewed by Shonhai et al. ([@CR42]). The aetiological agent of malaria tropica, *Plasmodium falciparum*, develops and thrives under physiologically divergent conditions throughout its life stages. Heat shock proteins are thought to play an important role in the development of *P. falciparum* as well as other human parasites (Sharma [@CR38]; Shonhai et al. [@CR41]; Shonhai et al. [@CR42]).

Heat shock protein 70 (Hsp70) and Hsp90 are some of the most studied molecular chaperones, proteins which themselves are responsible for the folding of other proteins in the cell. Hsp70 binds non-native proteins whilst substrates of Hsp90 are usually in native-like forms (Wegele et al. [@CR45]). Proteins that require both Hsp70 and Hsp90 to fold are thus transferred from Hsp70 to Hsp90 during the folding process. Eukaryotic Hsp90 participates in the conformational regulation of signal transduction molecules, such as tyrosine kinases and steroid hormone receptors. For example, steroid hormone receptors associate with Hsp90 in order for them to adopt conformational competence for hormone binding (Dittmar and Pratt [@CR10]).

In eukaryotes, the essential interaction between Hsp70 and Hsp90 is mediated by the Hsp70--Hsp90 organising protein (Hop; Nicolet and Craig [@CR26]). Both Hsp70 and Hsp90 possess C-terminally located EEVD motifs that interact with Hop via its tetratricopeptide repeat (TPR) domains, TPR1 and TPR2A motifs, respectively (Scheufler et al. [@CR35]). It is most likely that the Hsp70--Hsp90 functional partnership in *Plasmodium* spp. facilitates the folding of key proteins in the parasite cell, possibly those involved in signal transduction. PfHsp90 is known to play an essential role in the survival of the parasite and the antibiotic geldanamycin is known to inhibit its function (Banumathy et al. [@CR3]).

Of the six Hsp70-like proteins encoded by the *P. falciparum* genome, only the cytosol-nuclear localised chaperone, PfHsp70 possess the EEVD motif (Shonhai et al. [@CR41]) that is crucial for interaction between Hsp70 and Hop. PfHsp90 occurs in the cytosol and migrates to the nucleus in response to heat stress (Acharya et al. [@CR1]). Thus, PfHsp70 and possibly PfHsp90 possibly cooperate in the parasite cell. Although a Hop homologue (PF14_0324) has been identified in the *P. falciparum* genome (Acharya et al. [@CR1]), its function has not been characterised. Banumathy et al. ([@CR3]) observed the occurrence of PfHsp90 and PfHsp70 in functional units that were complexed to two other species of proteins with a molecular mass of around 50 and 60 kDa, respectively. Although not directly verified by experimental data, the authors proposed that the two proteins associating with PfHsp70 and PfHsp90 were *P. falciparum* cyophilin and PfHop. In addition, at least one TPR-rich protein, PP5 phosphatase from *P. Falciparum*, has been shown to interact with PfHsp90 (Dobson et al. [@CR11]; Kumar et al. [@CR21]).

So far. there is no direct experimental evidence for the existence of a functional PfHsp70--PfHsp90 partnership. However, the presence of PfHsp90 and PfHsp70 in common cellular compartments, coupled to data based on predictive bioinformatics suggest that the two chaperones may functionally interact through a PfHop-mediated pathway (Pavithra et al. [@CR30]). The possible existence of a Hop-mediated Hsp70--Hsp90 partnership in *P. falciparum* is important, given the essential roles of these proteins. Indeed, this pathway has been proposed as a potential anti-malarial drug target (Pesce et al. [@CR33]; Shonhai [@CR39]). The aim of the current study was to investigate the role of PfHop as a potential mediator of the PfHsp70--PfHsp90 pathway. We cloned, expressed and purified recombinant PfHop protein to facilitate its further characterisation. We further analysed the cellular localisation of PfHop and its association with PfHsp70 and PfHsp90.

Materials and methods {#Sec2}
=====================

Bioinformatics {#Sec3}
--------------

To map out the TPR domains in PfHop, Clustal W alignments of Hop homologues from *Plasmodium* species, human, mouse and yeast were performed utilizing the Bioedit program version 7.0.5.3 (Hall [@CR17]). A three-dimensional model of PfHop was generated by SWISS-MODEL (Arnold et al. [@CR2]; Guex and Peitsch [@CR16]; Schwede et al. [@CR37]). The images were subsequently visualised using the PyMol molecular graphics system, version 0.99rc6 (DeLano [@CR9]).

Peptide-directed PfHop and PfHsp90 antibody design and synthesis {#Sec4}
----------------------------------------------------------------

Anti-peptide antibodies specific to PfHop (PlasmoDB accession number: PF14_0324) and PfHsp90 (PlasmoDB accession number, PF07_0029) were generated commercially (Eurogentec) by immunisation of rabbits with the following synthetic peptides: TGEGNDAEERQRQQR, corresponding to amino acids 195--206 of the PfHop sequence and a mixture of two peptides (CIRYESITDTQKLSAE and CPKRAPFDM FENRKKR), corresponding to amino acids 45--59 and 364--377 of PfHsp90, respectively.

Cloning of PfHop, over-expression and purification of PfHop {#Sec5}
-----------------------------------------------------------

The coding sequence of PfHop (PlasmoDB accession number: PF14_0324) was PCR amplified from 3D7 gDNA using forward primer (5′-T**GCATGC**ATGGTTAACAAAGAAGAAGCTC-3′) with a *Sph*I site (in bold) and reverse primer (5′-T**CTGCAG**TTATCGTACCTTCAATATTCCAGC-3′) with a *Pst*I site (in bold) and inserted into the *Sph*I/*Pst*I sites of pQE30 (Qiagen). Plasmid integrity was verified by restriction digest and automated DNA sequencing.

To facilitate purification of PfHop recombinant protein, the protein was first overexpressed in *E. coli* XL1 Blue cells. The *E. coli* XL1 Blue cells were first transformed with pQE30/PfHop plasmid. Subsequently, one isolated recombinant colony from the YT agar plate was inoculated to YT broth containing 100 μg/ml ampicillin (Roth) followed by incubation at 37°C shaking incubator. At OD~600~ of 0.6, the cells were induced with 1 mM isopropyl-β-[d]{.smallcaps}-1-thiogalactopyranoside \[IPTG\] (Roth). Five hours after induction, the cells were harvested by centrifugation at 5,000 *g* for 20 min at 4°C. They were then re-suspended in non-reducing lysis buffer (300 mM NaCl, 10 mM imidazole, 10 mM Tris, pH 8.0, 1 mM phenylmethylsulphonyl fluoride \[PMSF\], and 1 mM lysozyme). Cell lysis was allowed to proceed for 20 min at room temperature (22°C), after which the lysate was frozen at −80°C, overnight. The cells were then thawed by mild sonication at amplitude setting of 50 for 7 cycles with 15-second pulse and five-second rest after each cycle. Soluble cell extract was derived after clarification by centrifugation at 5,000 *g* for 30 min at 4°C. The His-tagged PfHop protein that was in the soluble cell extract was allowed to bind to nickel-charged sepharose beads at 4°C for 4 h. The beads were washed using wash buffer (10 mM Tris, pH 7.5, 300 mM NaCl, 50 mM imidazole), and PfHop recombinant protein was then eluted using elution buffer (10 mM Tris, pH 7.5, 300 mM NaCl, 1 M imidazole). The eluted protein was extensively dialysed at 4°C against a storage buffer (10 mM Tris, pH 7.5, 300 mM NaCl, 50 mM imidazole, 0.8 mM DTT and 10% glycerol). The protein was subsequently concentrated with polyethylene glycol.

Construction of plasmid expressing PfHop-GFP {#Sec6}
--------------------------------------------

The PfHop coding sequence was amplified by PCR from gDNA (clone 3D7) using forward primer (5′-GG**CTCGAG**ATGGTTAACAAAGAAGAAGCTCAGAG-3′) with a *Xho*I site (in bold) and reverse primer (5′-GG**CCTAGG**TCGTACCTTCAATATTCCAGC-3′) with a *Avr*II site (in bold). The successful isolation and amplification of the PCR product were confirmed by agarose gel electrophoresis. The PCR product was recovered by gel purified and restricted with *Xho*I and *Avr*II. The PfHop encoding segment was inserted into the pARL-2-GFP vector (Przyborski et al. [@CR34]) between *Xho*I and *Avr*II restriction sites located in the multiple cloning site. The product was inserted in frame with a downstream GFP coding sequence to generate pARL-2-GFP/PfHop plasmid construct. Diagnostic restriction digestions using *Xho*I and *Avr*II were conducted to confirm the integrity of the pARL-2-GFP/PfHop plasmid construct. The plasmid was also sequenced to confirm that the PfHop encoding segment was inserted in frame with the GFP encoding sequence.

Parasite culture and preparation of parasite fractions {#Sec7}
------------------------------------------------------

*P. falciparum* 3D7 cells were cultured under standard conditions (Przyborski et al. [@CR34]; Trager and Jensen, [@CR44]). Sychronised parasites were harvested using Gelafundin flotation at the trophoite stage. Trophozoite-infected erythrocytes were subsequently washed in PBS (pH 7.4) and lysed using saponin (0.1%). Lysis was allowed to proceed on ice for 6 min with constant gentle mixing to facilitate the lysis. Parasites were collected by centrifugation at 36,000 *g* for 30 min at 4°C followed by an extensive wash step using PBS (pH 7.4). The parasite lysates were subjected to Western analysis to confirm the expression of PfHop. A host cell protein, glycophorin was also probed as a loading control. Images were acquired using X-ray film (Fuji super RX).

Immunofluorescence assays {#Sec8}
-------------------------

Immunofluorescence assays to investigate the localisation of PfHop and PfHop-GFP in parasite-infected erythrocytes were carried out as previously described (Spork et al. [@CR43]). Following fixation of parasite-infected red blood cells, localisation was examined using anti-PfHop primary antibody (purified IgG fraction, 1:100; this study), polyclonal anti-PfHsp70 primary antibodies (1:1,000; Pesce et al. [@CR32]) or polyclonal rabbit anti-PfHsp90 antibody (purified IgG fraction 1:100; this study). After extensive washing steps, the erythrocytes were thereafter incubated with cy3-conjugated goat anti-rabbit IgG secondary antibodies (1:2,000; DAKO Hamburg, Germany) for 2 h at room temperature. The erythrocytes were observed with fluorescence microscope (cell observer) using a 63× oil immersion objective. The images were acquired using Axiovision software package version 4.8.2. Image J software was used for pseudo-colouring and for preparation of merged co-localisation images. Negative control samples of erythrocytes incubated with respective rabbit pre-immune serum and secondary antibody were used to validate the specificity of the localisation signal.

Size exclusion chromatography {#Sec9}
-----------------------------

Size exclusion chromatography was conducted as previously described (Pesce et al. [@CR32]). Infected erythrocytes were suspended in PBS (pH 7.4) containing 0.15% (w/v) saponin for 10 min on ice followed by centrifugation at 5,000 *g* for 5 min. The pellet fraction of the parasite was washed three times with PBS (pH 7.4) followed by resuspension in 50 mM Tris, 150 mM NaCl (pH 7.4) including 1 mM PMSF and protease inhibitor cocktail (Pierce) and three freeze--thaw cycles. The parasite lysate was centrifuged at 20,000 *g* for 20 min at 4°C to separate soluble parasite lysate and cell debris. An aliquot containing 400 μg of total parasite lysate was injected into a 24-ml Superdex 200 column (GE Healthcare). Fractions of parasite cell lysate of 500 μl were recovered automatically. The proteins contained in the fractions were precipitated with 10% (w/v) trichloroacetic acid (TCA) on ice for 30 min and centrifuged. The protein pellet was subjected to Western analysis using anti-PfHsp90, anti-PfHsp70, and anti-PfHop antibodies. The secondary antibody used was HRP-conjugated goat anti-rabbit IgG (Dako, Germany, 1:1:2,000).

Immunoprecipitation analysis {#Sec10}
----------------------------

Parasites released by saponin lysis were resuspended in IP-lysis buffer (150 mM NaCl, 50 mM Tris--HCl, 0.1% NP-40, 1 mM PMSF, and protease inhibitor cocktail (Pierce)), and subjected to three freeze/thaw cycles. A soluble supernatant was collected by centrifugation (4°C, 36,000 × *g*). Anti-PfHsp70 antisera were added and the sample split into two aliquots. One aliquot was adjusted to 5 mM ATP and the other received no extra ATP. Antibody binding was allowed to occur overnight at 4°C on a rocking platform. Following this, protein A/G beads (Pierce) were added, and binding was allowed to proceed for 1 h. The immunoprecipitate was then collected by centrifugation at 1,000 × *g* for 5 min at 4°C and the pellet washed extensively with PBS (pH 7.4) before preparation of the samples for SDS-PAGE and Western analysis. Specificity of binding was controlled by monitoring binding to control agarose beads.

Results {#Sec11}
=======

Mapping of the TPR domains in PfHop {#Sec12}
-----------------------------------

Based on the Clustal W alignments conducted, PfHop possesses three TPR domains: an N-terminal TPR1 domain composed of residues 7--121, a centrally located TPR2A, at position 243--365 and a C-terminal TPR2B, at position 378--494 (Fig. [1](#Fig1){ref-type="fig"}). Residues that are known to be important in the interaction of the TPR domains of mouse Hop with either Hsp70 or Hsp90 (Odunuga et al. [@CR27]) are also conserved in PfHop (Fig. [1](#Fig1){ref-type="fig"}). Thus, based on sequence alignment data, PfHop presents itself as a typical member of these TPR-rich proteins. Although, Hop proteins whose sequences were analysed appear generally conserved across species, it is interesting to note that there is relative variation between plasmodial Hop proteins in comparison to the human, yeast and mouse homologues even within important functional domains such as the TPR segments and DP motifs (Fig. [1](#Fig1){ref-type="fig"}; Carrigan et al. [@CR5]). DP motifs are known to be important in the global fold of Hop and their disruption has been found to impair Hop function (Nelson et al. [@CR25]).Fig. 1Multiple sequence alignment of plasmodial, yeast and mammalian Hop homlogues. Multiple sequence alignment of TPR domains of Hop homologues from Pfal (*Plasmodium falciparum*, PlasmoDB accession number, PF14_0324), Pviv (*Plasmodium vivax*, NCBI accession number, XP_001616631.1), Pkno (*Plasmodium knowlesi*, NCBI accession number, XP_002260669.1), Pcha (*Plasmodium chabaudi*, NCBI accession number, XP_745506.1), Pber (*Plasmodium berghei*, NCBI accession number, XP_677465.1), Pyoe (*Plasmodium yoelii*, NCBI accession number, XP_731105.1), Hsap (*Homo sapiens*, NCBI accession number, NP_006810.1), Mmus (*Mus musculus*, NCBI accession number, BC003794.1), and Scer (*Saccharomyces cerevisiae*, NCBI accession number, CBZ50259.1). TPR domains are highlighted as follows: TPR1 (*red solid box*), TPR2A (*red dashed box*) and TPR2B \[*red dotted box*\] (Scheufler et al. [@CR35]). Amino acids that are implicated in TPR1--PfHsp70 and TPR2A--PfHsp90-1 interaction are indicated by *blue arrows* (Scheufler et al. [@CR35]; Odunuga et al. [@CR27]; [@CR28]). Residues constituting DP1 and DP2 repeat (Carrigan et al. [@CR5]) motifs are highlighted by green rectangles

The concave surfaces that are formed by the TPR domains of Hop provide interactive sites that can accommodate specific peptide binding (Scheufler et al. [@CR35]). Based on the three-dimensional model of TPR1 and TPR2A domains, PfHop possesses conserved residues in TPR1 (K11, N15) and TPR2A (K247, N251, K319) that are implicated in the interaction of Hop with Hsp70 and Hsp90 chaperones, respectively (Fig. [2](#Fig2){ref-type="fig"}; Scheufler et al. [@CR35]; Odunuga et al. [@CR28]). These residues appear to be surface-exposed on the TPR helical domains, suggesting that they may play an important role in binding PfHsp70 and PfHsp90 chaperones.Fig. 2PfHop model displays surface exposed residues implicated in interaction with PfHsp70 and PfHsp90. Schematic representation of PfHop showing the TPR domain as indicated by *rectangles highlighted in grey*. The numbers represent the starting and the ending amino acid residues of the three TPR domains. Ribbon representation of the three dimensional models of TPR1, TPR2A and TPR2B domains. Residues known to be crucial in the interaction of TPR1 and TPR2A with Hsp70 and Hsp90, respectively are represented in *sticks*. The models were generated by SWISS-MODEL (Arnold et al. [@CR2]; Guex and Peitsch [@CR16]; Schwede et al. [@CR37]) and rendered using PyMol (DeLano [@CR9])

Overexpression and purification of recombinant PfHop {#Sec13}
----------------------------------------------------

Recombinant PfHop protein was expressed in *E. coli* XL1 Blue cells as a species of approximately 66 kDa (Fig. [3](#Fig3){ref-type="fig"}). However, we also noticed a protein species of approximately 55 kDa, produced in *E. coli* together with the full length PfHop recombinant protein. The expressed lower molecular weight species, like the full length PfHop protein was produced upon induction of the cells with IPTG and did not appear in the control cells. Anti-PfHop antibodies were able to recognize both the full length Hop protein and the lower molecular weight species as confirmed by Western blotting (Fig. [3b](#Fig3){ref-type="fig"}). We concluded that the lower molecular species was either a truncated version of the full length PfHop protein or a product of an incomplete synthesis. We proceeded to purify PfHop by nickel affinity chromatography and were able to recover the full length PfHop protein (Fig. [3a](#Fig3){ref-type="fig"}). Fortunately, the species of lower molecular weight did not co-purify with PfHop protein, suggesting that this species had no polyhistidine tag attached (Fig. [3a, c](#Fig3){ref-type="fig"}). Therefore, it is likely that the species of lower molecular weight was an N-terminally truncated version of PfHop.Fig. 3Expression and purification of recombinant PfHop protein. **a** SDS-PAGE analysis for the expression and purification of recombinant PfHop protein. PfHop was expressed in *E. coli* XL1 Blue cells transformed with pQE30/PfHop plasmid. Lane M represents molecular weight markers (in kDa) as indicated on the left hand side; lane C, represents the total extract for cells transformed with pQE30 plasmid after IPTG induction; lane 0, represents total extract for cells transformed with pQE30/PfHop plasmid prior to IPTG induction; lanes 1--ON, represent total extract for cells transformed with pQE30/PfHop plasmid collected hourly and overnight, respectively; lane F, represents the flow through; lane W, represents wash sample; and lane P, represents eluted PfHop protein. **b** Western analysis of PfHop using anti-PfHop and **c** Western analysis of PfHop using anti-His antibodies. The results are representative of at least three independent experiments

Localisation of PfHop {#Sec14}
---------------------

The localisation of PfHop in *P. falciparum* cells at the trophozoite stage was investigated by immunofluorescence analysis (IFA) using anti-PfHop antibodies that we developed (Fig. [4a](#Fig4){ref-type="fig"}). The fluorescence signal (red signal) was observed in the cytosol of parasites that had been cultured at 37°C. To further investigate the cellular localisation of PfHop, we created a transgenic parasite line expressing PfHop attached to a C-terminal GFP tag. PfHop-GFP localised largely to the body of the parasite (Fig. [4b](#Fig4){ref-type="fig"}). The GFP signal was not detected in the nucleus, suggesting that PfHop may not localise to the nucleus under normal growth conditions. By indirect immunofluorescence, we investigated whether PfHop-GFP co-localises with PfHsp90. It appears that PfHop-GFP and PfHsp90 co-localise in the cytosol and their distribution assumed a uniform pattern in the cell (Fig. [4c](#Fig4){ref-type="fig"}). PfHop-GFP and PfHsp70 co-localised in the cytosol; however, they associated less uniformly than PfHop-GFP and PfHsp90 (Fig. [4c, d](#Fig4){ref-type="fig"}). The expression of PfHop-GFP by the transfected parasites was confirmed by Western blot analysis (Fig. [4e](#Fig4){ref-type="fig"}). As loading control, a Western blot was conducted using antibodies recognising *P. falciparum* aldolase (Fig. [4e](#Fig4){ref-type="fig"}, third panel).Fig. 4Localisation and expression of PfHop-GFP by parasites in human red blood cells. **a** Localisation of PfHop in *P. falciparum* cells; panels show a DIC image, nuclear stain (Hoechst), distribution of PfHop, merge and overlay. **b** Panels show a DIC image, nuclear stain (Hoechst), distribution of PfHop-GFP, merge and overlay. **c** Panels show a DIC image, nucleus (Hoechst), distribution of PfHop-GFP, distribution of PfHsp90, merge and overlay for PfHsp90--PfHop-GFP co-localisation. **d** Panels show DIC image, stain (Hoechst), distribution of PfHop-GFP, distribution of PfHsp70, merge and overlay. **e** Western blot analyses to confirm the expression of PfHop-GFP. *First panel*, Western blot conducted using polyclonal anti-PfHop antibodies; *second panel*, Western blot conducted using monoclonal anti-GFP antibodies; and *third panel*, Western blot conducted as loading control conducted using polyclonal anti-PfAldolase antibodies. The results are representative of at least three independent experiments

Size exclusion chromatography and co-immunoprecipitation analysis {#Sec15}
-----------------------------------------------------------------

Size exclusion chromatography was performed to investigate whether PfHop, PfHsp70, PfHsp90 and PfJ4, a potential Hsp40 co-chaperone of PfHsp70 (Pesce et al. [@CR32]) existed as a complex in parasite cells. The eluted fractions obtained were subjected to Western analysis using anti-PfHop, anti-PfHsp70, anti-PfHsp90 and anti-PfJ4 antibodies (Pesce et al. [@CR32]; Fig. [5a](#Fig5){ref-type="fig"}). PfHsp90, PfHsp70 and PfHop all appeared in an apparent fraction of approximately 400 kDa in size. Several possibilities may underpin the observed findings. One interpretation is that all the three proteins are in a common complex. It is also possible that PfHsp90, PfHsp70 and PfHop may have been eluted in independent complexes that were apparently of similar sizes, thus eluting in the same fraction. Alternatively, this could represent independent homo-oligomers that approximated each other in size, and thus were eluted in the same fractions, but were not necessarily associated with one another. A previous study suggested that a type II (Cheetham and Caplan [@CR6]) Hsp40 protein, PfJ4 associated with PfHsp70 (Pesce et al. [@CR32]). However, it seemed that PfJ4 was not part of the putative complex made up of PfHop, PfHsp70 and PfHsp90 (Fig. [5a](#Fig5){ref-type="fig"}).

Formation of the Hsp70--Hop--Hsp90 complex is known to be nucleotide sensitive. As a result, we sought to establish whether PfHop, PfHsp70 and PfHsp90 association was nucleotide-sensitive. A co-immunoprecipitation study was conducted using anti-PfHsp70 antibodies and passing parasite lysate through the column. In one instance, 5 mM ATP was added to the parasite lysate before conducting the immunoprecipitation (lane '+ATP', Fig. [5b](#Fig5){ref-type="fig"}) and the experiment was repeated without adding ATP to the lysate (lane '−ATP', Fig. [5b](#Fig5){ref-type="fig"}). Hop associates preferably with Hsp70 when the latter is bound to ADP. In the absence of added ATP, it likely that most of the PfHsp70 protein in the lysate was either bound to ADP or was in a nucleotide-free state. In the absence of added ATP, PfHsp70 immunoprecipitated along with PfHop (lane '−ATP', Fig. [5b](#Fig5){ref-type="fig"}). When ATP was added to the lysate, we could not detect PfHop in the PfHsp70 complex (lane '+ATP', Fig. [5b](#Fig5){ref-type="fig"}). PfHsp90 was detected when its association with PfHsp70 was investigated both in the presence and absence of added ATP. PfHsp90 appeared on the Western blot as a species of approximately 90 kDa (Fig. [5b](#Fig5){ref-type="fig"}). However, in the absence of ATP, more PfHsp90 protein associated with PfHsp70 than when ATP was added to the parasite lysate (Fig. [5b](#Fig5){ref-type="fig"}).Fig. 5PfHop, PfHsp70, PfHsp90 and PfJ4 may associate in a heterologous complex. **a** The presence of PfHop, PfHsp70, PfHsp90 and PfJ4 in the elution fractions obtained by size exclusion chromatography was determined by Western analysis using corresponding antibodies. Approximate molecular weights (in kDa) associated with select fractions are given (*top panel*). **b** Co-immunoprecipitation of PfHop, PfHsp70 and PfHsp90 using anti-PfHop antibodies, in the absence and presence of ATP. PfHop and immunoglobulin heavy chain are shown by the arrows. The results are representative of at least three independent experiments

Discussion {#Sec16}
==========

PfHsp70 and PfHsp90 chaperones of *Plasmodium* spp. are known to play essential roles in the development of the parasites. PfHsp70 and PfHsp90 have been characterised extensively and their roles in the development of *P. falciparum* are well documented (Banumathy et al. [@CR3]; Sharma [@CR38]; Shonhai et al. [@CR40]; [@CR41]). It is likely that these chaperones are functionally linked. In mammals, the TPR-rich Hop protein is known to modulate interaction of Hsp70 and Hsp90 chaperones. To the best of our knowledge, this is the first study to provide experimental evidence suggesting a possible role for the *P. falciparum* Hop homologue in mediating the functional partnership between PfHsp70 and PfHsp90.

Based on bioinformatics analysis, PfHop possesses conserved TPR1 and TPR2A domains that are implicated in facilitating the interaction of Hop with Hsp70 and Hsp90 in mammalian cells (Fig. [1](#Fig1){ref-type="fig"}; Odunuga et al. [@CR27]; [@CR28]). Residues that have direct contact with Hsp70 and Hsp90 are conserved in PfHop and they protrude on the helical surfaces of the respective TPR domains (Fig. [2](#Fig2){ref-type="fig"}), thus positioning them for the possible interaction of PfHop with its chaperone clients. Overall, PfHop exhibits conserved structural features of a typical Hop protein. However, although most structural motifs are conserved in Hop proteins, it is interesting to note that plasmodial Hop proteins exhibit select distinct functional domains, compared to their counterparts of yeast and mammalian origin. The relative variations in sequences exhibited between plasmodial Hop proteins and their counterparts from mouse, human as well as yeast even in important domains such as TPR and DP motifs (Fig. [1](#Fig1){ref-type="fig"}), could represent potential functional variation in the Hop-mediated pathways in these species. For example, DP repeats have been found to modulate Hop function by influencing the global folding status of Hop (Nelson et al. [@CR25]) and thus variation within these domains could mirror functional specialisation of Hop proteins. It is thought that the less conserved segments of Hop outside its TPR domains have influence on the overall conformations of the helical turns of the TPR domains, thus are capable of imparting unique structural features to Hop molecules from different species (D\'Andrea and Regan [@CR8]). Therefore, the sequence variations observed between PfHop and human Hop may make PfHop amenable for selective inhibition using chemicals that may not interfere with human counterpart.

In mouse cells, Hop predominantly occurs in the cytosol under normal growth conditions and shuttles between the nucleus and the cytosol (Lässle et al. [@CR22]; Longshaw et al. [@CR24]; [@CR23]). An investigation into the cellular distribution of PfHop in parasites at the trophozoite stage showed that the protein is localised to the cytosol (Fig. [4](#Fig4){ref-type="fig"}). As PfHop is implicated in mediating the interaction between PfHsp70 and PfHsp90, we investigated the distribution and co-localisation of these three proteins. Indeed, PfHop displayed a similar cytosolic localisation profile to PfHsp90 (Fig. [5b](#Fig5){ref-type="fig"}), suggesting that the two proteins may associate. Although, PfHop-GFP and PfHsp70 exhibited overlapping cytosolic co-localisation signals, the PfHsp90--PfHop-GFP co-localisation signal was more uniform than that for PfHsp70--PfHop-GFP (Fig. [4b, c](#Fig4){ref-type="fig"}). It is possible that PfHop associates more closely with PfHsp90 than with PfHsp70. Cytosolic co-localisation of Hop and Hsp70 homologues from *Trypanosoma cruzi*, another member of the apicocomplexan family, has been reported (Schmidt et al. [@CR36]). Previously, it was proposed that PfHsp70 and PfHsp90 were found to co-elute complexed to a 60 kDa species, which was predicted to be PfHop (Banumathy et al. [@CR3]). Findings from this study point to the possible existence of a PfHop-mediated partnership between PfHsp70 and PfHsp90 as has been previously proposed (Pesce et al. [@CR33]; Shonhai [@CR39]).

We performed size exclusion chromatography to investigate if PfHop may occur in complexes with PfHsp90 and PfHsp70 (Fig. [5a](#Fig5){ref-type="fig"}). We obtained fractions in which PfHop was present along with PfHsp70 and PfHsp90. This suggests the possible existence of a PfHsp70--PfHop--PfHsp90 complex in *P. falciparum*. However, we cannot formally rule out the possibility that the three proteins may have occurred in independent complexes that may have given rise to oligomeric units of similar apparent sizes.

Unusually, we also obtained a fraction containing a complex of about 440 kDa in which PfHsp90 and PfHsp70 occurred in the absence of PfHop (Fig. [5a](#Fig5){ref-type="fig"}). Whilst this may represent possible elution of PfHsp90 and PfHsp70 in independent complexes, the interaction of Hsp70 and Hsp90 through a Hop independent partnership has been reported in other living organisms such as *Neurospora* (Freitag et al. [@CR13]). Interestingly, we also yielded several fractions of varying sizes in which PfHsp70 and PfHop occurred in the absence of PfHsp90. This was unexpected, as it is known that Hsp90 improves the affinity of Hsp70 for Hop binding (Hernández et al. [@CR18], [@CR19]). However, it is also known that binding of Hsp90 to Hsp70--Hop complex, reduces the number of Hsp70 binding sites on Hop from two to one binding site, although overall the binding of Hsp90 improves affinity of Hsp70 for Hop (Hernández et al. [@CR19]). Thus, Hsp90 binding may also be perceived as putting a strain on the Hsp70--Hop complex. In addition, in the absence of Hsp90, the Hsp70--Hop complex is stabilised by other protein interactors, particularly Hsp40. This may further mirror the complexity of the mechanism by which the Hsp70--Hop--Hsp90 pathway is governed. For example, a non-canonical Hop protein with a missing TPR1 domain from *Caenorhabditis elegans* (CeHop) has been described as capable of binding both Hsp70 and Hsp90 through the TPR2A domain (Gaiser et al. [@CR15]). However, this essential protein could not bind both Hsp70 and Hsp90 at once. This could suggest that Hop may independently associate with Hsp90 and Hsp70. Interestingly, none of the fractions we obtained had PfHsp90 and PfHop in the absence of PfHsp70, in spite of the fact that Hsp90 is known to interact with Hop in the absence of Hsp70 (Hernández et al. [@CR19]). This may be due to the transient and dynamic nature of the association between PfHsp90 and PfHop since the immunofluorescence data suggested a strong association between PfHsp90 and PfHop (Fig. [4b](#Fig4){ref-type="fig"}).

Previous studies proposed that Hsp40 co-chaperones (belonging to the type I and type II subfamilies; Cheetham and Caplan [@CR6]) are involved in the assembly of the Hsp70--Hop--Hsp90 complex (Cintron and Toft [@CR7]). In this study, we sought to investigate if PfJ4, a type II Hsp40 known to associate with PfHsp70 (Pesce et al. [@CR32]), would occur in the PfHsp70--PfHop--PfHsp90 complex. PfJ4 was not eluted in the fraction in which both PfHsp70 and PfHsp90 occurred (Fig. [5a](#Fig5){ref-type="fig"}). This suggests that PfJ4 may not be involved in the formation of this complex. We recently described a type I Hsp40 from *P. falciparum* (PfHsp40) that functionally co-operates with PfHsp70 in vitro (Botha et al. [@CR4]). PfHsp40 may possibly be one of the *P. falciparum* Hsp40 proteins that are involved in the formation of the PfHsp70--PfHop complex, but this possibility still needs to be experimentally verified.

Based on co-immunoprecipitation analysis, PfHsp70 associated with both PfHsp90 and PfHop (Fig. [5b](#Fig5){ref-type="fig"}). As expected, in the absence of added ATP, PfHsp70 interacted with more PfHop protein than in the presence of added ATP (Fig. [5b](#Fig5){ref-type="fig"}). This is in agreement with a previous study that proposed that Hop binds to Hsp70 when the latter is complexed to ADP (Johnson et al. [@CR20]). It seems in the presence of added ATP, less PfHsp90 was part of the PfHsp70 complex than was involved in the formation of this complex in the absence of added ATP (Fig [5b](#Fig5){ref-type="fig"}). Thus, ATP may have inhibited the association between PfHsp70 and PfHop, resulting in less PfHsp90 protein associating with PfHsp70. It seems that the possible association between PfHop and PfHsp70 (Fig. [5b](#Fig5){ref-type="fig"}) was sensitive to nucleotide, suggesting that PfHop and PfHsp70\'s association represents a functional interaction.

A study by Famin and Ginsburg ([@CR12]), observed that PfHsp70 and PfHsp90 both associate with ferriprotoporphyrin IX, a receptor of chloroquine that accumulates in chloroquine treated parasites. Ferriprotoporphyrin IX is thought to modulate the susceptibility of the parasite to chloroquine (Fitch [@CR14]). This suggests that PfHsp70 and PfHsp90 may jointly facilitate the folding of proteins of parasitic origin that are implicated in regulating antimalarial drug efficacy. Interestingly, PfHsp90, PfHsp70 and PfHop were previously found to be distinctly upregulated in a group of clinical malaria patients (Pallavi et al. [@CR29]). This suggests that the expression of these proteins may share a common regulatory trigger, and that their expression correlates with clinical malaria progression. As further evidence of their important role, plasmodial heat shock proteins have been described as potential antimalarial drug targets (reviewed in Pesce et al. ([@CR33]) and Shonhai ([@CR39]). Plasmodial heat shock proteins may be targeted in combination therapies by developing drugs that target these molecules and other malarial protein drug targets that fold through pathways that are facilitated by the parasite\'s chaperone machinery (reviewed in Pesce et al. [@CR33]; Shonhai [@CR39]).

The possible role of PfHop in coordinating the PfHsp70--PfHsp90 functional pathway might lead to interesting prospects in the search for alternative antimalarial therapies. For example, some pyrimidinones with antimalarial activity and are known to bind to the EEVD motif of Hsp70. These compounds may be able to inhibit interaction of Hsp70 with its co-chaperones such as Hop, Hsp40 and client substrates (Shonhai [@CR39]). Thus, an understanding of the PfHop mediation of PfHsp70--PfHsp90 pathway could present a potential antimalarial drug target. This is particularly an important pathway to target, as inhibition of the Hsp70--Hsp90 pathway is known to lead to degradation of client proteins that depend on this pathway for folding (Whitesell and Lindquist [@CR46]). Since both PfHsp70 and Hsp90 play essential roles in the folding of malarial proteins (Pavithra et al. [@CR31]; Shonhai et al. [@CR41]), targeting this pathway has conceivable deleterious effects to the parasite.

In conclusion, we have provided evidence that PfHop potentially exists in association with PfHsp70 and PfHsp90. Further studies need to be undertaken in order to understand the mechanism by which PfHop modulates this pathway in the malaria parasite and to understand if there may be variations between the two pathways in the host and malaria parasite towards the development of possible malaria intervention strategies.
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